Pay in 4 interest-free payments of $10.00 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification
Molecular Weight: 603
2-hydroxyglutarate (2HG)
(2009) J Med Chem
It has >30-fold selectivity over other HDACs
RKI-1447 - CAS# 1342278-01-6 Catalog No.:M60415-2S VR23: A Quinoline-Sulfonyl Hybrid ProteasomeRKI 1447, CAS No. 1342278 01 6, is a potent inhibitor of the Rho associated ROCK kinases with anti invasive and antitumor activities in breast cancer. RKI 1447 is a Type I kinase inhibitor that binds the ATP binding site through interactions with the hinge region and the DFG motif. RKI 1447 suppressed phosphorylation of the ROCK substrates MLC 2 and MYPT 1 in human cancer cells. Product information CAS Number: 1342278 01 6 Molecular Weight: 326. 37
US$ 1117.50
US$ 169.95
US$ 16.49
US$ 54.60